Susan Groshen

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Topics

Oxide Nanoparticles

Acute Lymphoblastic Leukemia

Placebo Controlled

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pharmaceutical statistics

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Paul H Frankel, Susan Groshen, Jan H Beumer, Laura Cleveland, Edward S Kim, Judith E Karp
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Paul H Frankel, Susan Groshen, Jan H Beumer, Laura Cleveland, Edward S Kim, Judith E Karp
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sarmad Sadeghi, David I Quinn, Tanya Dorff, Sumanta Kumar Pal, Susan Groshen, Denice Tsao-Wei, Rahul A Parikh, Michael Devitt, Mamta Parikh, Alexandra Jackovich, Nora Ruel, Nicholas J Vogelzang, Earle Burgess, Imran Siddiqi, Inderbir S Gill, Primo N Lara, Robert Dreicer, Parkash S Gill
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Steven G DuBois, Meaghan P Granger, Susan Groshen, Denice Tsao-Wei, Lingyun Ji, Anasheh Shamirian, Scarlett Czarnecki, Fariba Goodarzian, Rachel Berkovich, Hiroyuki Shimada, Judith G Villablanca, Kieuhoa T Vo, Navin R Pinto, Yael P Mosse, John M Maris, Suzanne Shusterman, Susan L Cohn, Kelly C Goldsmith, Brian D Weiss, Gregory A Yanik, Clare J Twist, Meredith S Irwin, Daphne A Haas-Kogan, Julie R Park, Araz Marachelian, Katherine K Matthay
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (31) (2021)
Lingyun Ji, Juan Pablo Lewinger, Mark Krailo, Susan Groshen, David V Conti, Shahab Asgharzadeh, Richard Sposto
Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. Pharmaceutical statistics 18 (6) (2019)
Steven G DuBois, Yael P Mosse, Elizabeth Fox, Rachel A Kudgus, Joel M Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M Maris, Clare J Twist, Kelly Goldsmith, M Meaghan Granger, Brian D Weiss, Julie R Park, Margaret E Macy, Susan L Cohn, Greg Yanik, Lars M Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K Matthay, Araz Marachelian
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 24 (24) (2018)